Why Vertex Stock Got Mashed on Monday
The stock of niche financial software company (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly earnings report that many considered to be underwhelming. By contrast, the benchmark S 500 index rose on the day, closing slightly (0.2%) higher.
That morning, Vertex revealed that its total revenue was slightly over $192 million in the third quarter, a figure that was up by nearly 13% year-over-year. Subscriptions, which form the bulk of its top line, grew by the same rate to almost $165 million.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
420,00 €
1,27 %
Die Vertex Pharmaceuticals Inc. Aktie ist im Trend: Deutlich mehr Buy- als Sell-Einschätzungen.
Ein leicht positives Potenzial wird für Vertex Pharmaceuticals Inc. mit einem Kursziel von 467 € im Vergleich zu 420.0 € gesehen.
